Fig 2: Early-stage coordinated responses of T cells, mature DCs, and plasmablasts in mild patients(A) PCA plots of the samples from different groups.(B) Volcano plots of different immune features in MP versus HC. The selected list of significantly increased or decreased subsets (p = 0.05 and fold change =2) are marked in red and green, respectively.(C–G) Frequency of Ki67+ cells (C), CD38+ cells (D), HLA-DR+CD38+ cells (E), T-bet+Ki67+ cells (F), and EOMES+Ki67+ cells (G) among CD8 T cells.(H and K) Representative flow-cytometry plots of the expression of T-bet and Ki67 on CD8 T cells (H) or the expression of CD38 and HLA-DR (K) at D1.(I and J) Frequency of Ki67+ cells (I) and T-bet+Ki67+ cells (J) among CD4 T cells.(L and M) Frequency of HLA-DR+CD38high (mature DC) among CD3-CD19-CD14-HLA-DR+ cells (L) and of CD27highCD38high plasmablasts among CD3-CD19+IgD- B cells (M).(N, O, Q, and R) Correlation between the frequency of CD38+ among CD8 T cells or the frequency of HLA-DR+CD38+ cells among CD4 T cells at D1 and anti-SARS-CoV-2N-specific IgG titers at D21 from ASP and MP (N and O) or from HP (Q and R).(P and S) Correlation between the frequency of mature DC among CD3-CD19-CD14-HLA-DR+ cells at D1 and anti-SARS-CoV-2N-specific IgG titers at D21 from ASP and MP (P) or from HP (S).ASP, asymptomatic patients, n = 14; AU, arbitrary unit; HC, household controls, n = 26; HP, hospitalized patients, n = 15; MP, mild patients, n = 63; Tconv, FOXP3-CD4 conventional T cells; D1/D14/D21, day 1/day 14/day 21. Data represent individual values from all biological replicates; mean ± SD. p values in (C–G), (I), (J), and (K–M) were determined by the Kruskal-Wallis (non-parametric) test and corrected using Dunn’s multiple comparisons test. Spearman’s correlation was used in (N) to (S). ns, not significant; *p = 0.05, **p = 0.01, ***p = 0.001. See also Figures S2–S4.